✦ LIBER ✦

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer : A Phase II study

✍ Scribed by Matthew R. Smith; Donald Kaufman; William Oh; Kimberly Guerin; Michael Seiden; Thomas Makatsoris; Judith Manola; Philip W. Kantoff

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 67 KB
Volume: 89
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20001015)89:8<1824::aid-cncr24>3.0.co;2-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

Treatment of androgen-independent prosta

Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study

✍ Jeffrey F. Williams; Heather J. Muenchen; Jeffrey M. Kamradt; Susan Korenchuk; K 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 1 views

Gemcitabine and vinorelbine in advanced

Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma : A Phase II study

✍ Rogerio Lilenbaum; Roberto Cano; Michael Schwartz; Leonard Siegel; Jose Lutzky; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

The authors conducted a Phase II study to evaluate the activity of the combination of gemcitabine and vinorelbine in patients with advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS. Patients were eligible if they had Stage IIIB (malignant pleural effusion) or Stage IV NSCLC, no prior chemo

A phase II trial of estramustine and eto

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)

✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over

A phase II study of high-dose estrogens

A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

✍ Dennis L. Citrin; Merrill S. Kies; Carl-Bertil Wallemark; Jan Khandekar; Edward 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB 👁 1 views

A phase II study of piritrexim in combin

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer

✍ Everett E. Vokes; Isaiah W. Dimery; Charlotte D. Jacobs; Daniel Karp; Arturo Mol 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 1 views

Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day